Abcam, ab320792, Human Apolipoprotein CI/Apo-CI ELISA Kit- Intracellular

Size: 1 x 96Tests / 1 x 384Tests / 10 x 96Tests
Human Apolipoprotein CI/Apo-CI ELISA Kit- Intracellular is a single-wash 90-min Simplestep used to quantify Human Apolipoprotein CI/Apo-CI with a sensitivity of 7.3 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Different formats for different needs: 10x96 plates for bulk orders and 384-well plate for higher throughput - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate, Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 7.3 pg/mL,
Range:37.5 - 2400 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human Apolipoprotein CI/Apo-CI SimpleStep ELISA® kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Apolipoprotein CI/Apo-CI protein in Cell Lysate, Tissue extracts. Quantitate Human Apolipoprotein CI/Apo-CI with 7.3 pg/ml sensitivity.
SimpleStep ELISA
technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details. Our SimpleStep ELISA
technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips, available in 10-pack (10 x 96-well plates)
-Also available in a fully validated 384-well format.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein CI (Apo-CI) plays a mechanical role in lipid metabolism where it acts as an inhibitor of lipoprotein lipase and hepatic lipase hindering lipolytic activity. It is also known as 'apo 250' and 'apo atv20' with a molecular mass of approximately 6.6 kDa. Apo-CI is primarily expressed in the liver and secreted into the plasma where it associates with high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL).
Biological function summary
Apo-CI influences plasma triglyceride levels and cholesterol homeostasis. It plays a role in lipid transport and metabolism by modulating the binding of other apolipoproteins such as apo A-IV and interfering with the binding of lipoproteins to their receptors. Apo-CI is part of a complex of apolipoproteins that regulate lipid metabolism working in tandem to balance lipid and cholesterol levels in the body.
Pathways
Apo-CI is actively involved in the lipoprotein metabolism pathway and cholesterol efflux pathway. These pathways are important in maintaining lipid balance and cardiovascular health. Apo-CI is related to other apolipoproteins within these pathways such as apo E and apo A-I. Its function in modulating lipoprotein receptor interactions aligns with the broader mechanisms of these pathways in lipid and cholesterol regulation.
Elevated levels of Apo-CI are associated with hyperlipidemia and cardiovascular disease. These conditions may result from its inhibitory effects on lipase activity leading to increased triglyceride levels. Apo-CI's interaction with other apolipoproteins such as apo B and apo E is linked to its role in the pathogenesis of these disorders. Understanding Apo-CI's involvement in these diseases can guide therapeutic strategies aimed at regulating its expression and function.